

Supplementary Materials

Supplementary Figure 1. PRISMA Flow Diagram



BVZ = bevacizumab



Drug Regimen

Supplementary Figure 2. Accumulating Evidence and Research Organization (AERO) Graph


BVZ first-line mBC Research Portfolio: 52 trials, 36 different regimens studied.

Each node corresponds to a single clinical trial. Nodes are arranged by time of study start date (as reported on ClinicalTrials.gov) along the x-axis and drug regimen tested along the y-axis. No studies evaluated bevacizumab as monotherapy, therefore all regimens listed are additions to bevacizumab. Node size corresponds to the trial sample size. Node color represents the trial outcome, either with respect to overall survival (OS) benefit or its primary endpoint (when a hazard ratio for OS is not reported). Green nodes are favorable to bevacizumab, red nodes are unfavorable or were terminated, and yellow nodes mixed. Studies that included bevacizumab in all study arms are also considered mixed and yellow. Blue nodes are active trials (at the time of this analysis). Gray nodes are completed according to ClinicalTrials.gov, but the results are unknown. The dashed lines mark the FDA's accelerated approval period for bevacizumab from February 2008 (green) to November 2011 (red). BVZ = bevacizumab; mBC = metastatic breast cancer.

Supplementary Figure 3. Forest plot of cumulative meta-analysis on the effect of bevacizumab on the hazard ratio of progression-free survival over time with unpublished trial removed

			Cum.	Cum.		Cumulative Hazard ratio
Study	Exp	Ctrl	Exp	Ctrl		of PFS (95% CI)
Miller et al., 2007	347	326	347	326	+	0.60 (0.51, 0.70)
+ Miles et al., 2010	247	241	594	567	-	0.68 (0.53, 0.86)
+ Robert et al.,2011	409	206	1003	773	-	0.68 (0.58, 0.79)
+ Martin et a l ., 2011	97	94	1100	867		0.69 (0.60, 0.78)
+ Gianni et al., 2013	216	208	1316	1075	-	0.71 (0.63, 0.81)
+ Martin et al., 2015	190	184	1506	1259		0.73 (0.65, 0.82)
+ Miles et al., 2016	238	233	1792	1540		0.72 (0.65, 0.80)
				.5		 1 2


The graph shows a cumulative meta-analysis performed by adding individual trials chronologically and summarizing the point estimate as each new trial is added. The symbol plus before each trial indicates that the point estimate (ie, hazard ratio) of that trial is pooled with the previous summary estimate. The final result is a trial-level cumulative estimate over time and corresponding 95% confidence intervals. The diamonds represent the cumulative point estimates while the horizontal segments represent the 95% confidence intervals. Exp = number of participants in the experimental group; Ctrl = number of participants in the control group; Cum. Exp = cumulative number of participants in the experimental group; PFS = Progression Free Survival.



Supplementary Figure 4. Forest plot of cumulative meta-analysis on the effect of bevacizumab on the hazard ratio of overall survival over time with unpublished trial removed

The graph shows a cumulative meta-analysis performed by adding individual trials chronologically and summarizing the point estimate as each new trial is added. The symbol plus before each trial indicates that the point estimate (ie, hazard ratio) of that trial is pooled with the previous summary estimate. The final result is a trial-level cumulative estimate over time and corresponding 95% confidence intervals. The diamonds represent the cumulative point estimates while the horizontal segments represent the 95% confidence intervals. Exp = number of participants in the experimental group; Ctrl = number of participants in the control group; Cum. Exp = cumulative number of participants in the experimental group; OS = Overall Survival.

Supplementary Figure 5. Association of trial-level PFS effects and OS effects with unpublished trial removed



The graph shows the association of trial-level progression-free survival (PFS) and overall survival (OS) effects expressed as hazard ratios. The solid line represents equality between OS and PFS effects. The dashed line represents the estimated slope of the linear association from the random effects model. Areas of circles are proportional to trial sample sizes and horizontal and vertical line segments represent 95% confidence intervals for the trial-level hazard ratios.

Supplementary Table 1.Parameters for nonlinear mixed-effects model for the association of log HR for OS and log HR for PFS, excluding unpublished trials

•	<i>,</i> 0 1		
Parameter*	Estimate	Standard error	
α	0.029	0.288	
β	0.398	0.792	
μ	-0.332	0.055	
g	0	0.001	
σ^2	0.007	0.010	

* α = intercept of the linear relationship between the log HR for OS and log HR for PFS (when the HR for PFS is 1.0, the estimated HR for OS is $e^{0.045} = 1.05$; β = coefficient of the linear relationship between the log HR for OS and log HR for PFS; μ = average log HR for PFS across trials; corresponding to a HR of $e^{-0.332}$ =0.72; g = variance of log HR for OS across trials that is not explained by PFS. σ^2 = variance of log HR for PFS across trials;

References

- 1. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine. 2007;357(26):2666–2676.
- Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2– negative metastatic breast cancer. Journal of Clinical Oncology. 2010;28(20):3239–3247.
- 3. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. Journal of Clinical Oncology. 2011;29(10):1252–1260.
- 4. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. The lancet oncology. 2011;12(4):369–376.
- Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Journal of clinical oncology. 2013;31(14):1719–1725.
- 6. Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. Journal of Clinical Oncology. 2015;33(9):1045–1052.
- 7. Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer. 2017;70:146–155.